SummaryThe anti‐hypertensive effects of atenolol (Tenormin) 50 mg, a potassium‐sparing diuretic (half‐strength Moduretic) comprising hydrochlorothiazide 25 mg plus 2.5 mg amiloride hydrochloride, and the ‘free’ combination of atenolol and diuretic were compared in elderly hypertensive patients aged 60‐79 years.After a four‐week run‐in period on placebo, patients were randomly assigned, in a double‐blind manner, to atenolol or diuretic treatment, each for four weeks. Thereafter patients were given the ‘free’ combination for a further four weeks and this treatment was continued for six months.Blood pressure and heart rate were measured after the patient had rested for five minutes supine and after two minutes standing. These blood pressure measurements were made at least 24 hours after the preceding dose using a Random Zero sphygmomanometer. Results from 26 of the 27 patients entered into the study showed an advantage for combination therapy combined with either atenolol or diuretic treatment alone.No significant difference was found between treatments in the frequency of supraventricular and ventricular ectopic beats occurring in six patients who underwent 24‐hour ambulatory ECG monitoring. However, ectopic activity was reduced in some patients during beta‐blocker treatment.Few adverse effects occurred with any treatment. Three patients withdrew during the placebo period and three withdrew while taking active treatment.This study has shown that the combination of atenolol, hydrochlorothiazide and amiloride hydrochloride is an effective, safe, well‐tolerated antihypertensive drug regimen when used once daily in elderly hypertensive patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.